CellVax

Executive Summary

CellVax is a Singapore-based biotechnology company pioneering cell-based vaccines and immunotherapies for oncology. Its proprietary platform engineers antigen-presenting cells to prime potent, specific anti-tumor immune responses. The company is currently advancing a lead autologous therapy through Phase 2 clinical trials for multiple solid tumor indications. With $450 million raised to date and a clear vision to develop off-the-shelf allogeneic versions, CellVax aims to address key limitations of personalized cell therapies, including manufacturing complexity and cost. The company operates in a competitive but rapidly evolving landscape, yet its differentiated approach and strong financial backing position it as a potential leader in next-generation cancer vaccines. CellVax's near-term focus is on generating compelling Phase 2 efficacy and safety data for its lead candidate. Success could unlock significant value through regulatory acceleration, partnerships with larger pharma, or expansion into additional indications. The company is also advancing preclinical work on an off-the-shelf version, which would dramatically expand its addressable market. With a seasoned management team and a deep pipeline, CellVax represents a high-risk, high-reward opportunity in the oncology immunotherapy space. The conviction score reflects the promising platform and strong funding history but acknowledges clinical development risk and competition.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 interim data readout for lead autologous therapy70% success
• Q4 2026Strategic partnership or licensing deal for Asian markets50% success
• H1 2027IND filing for off-the-shelf allogeneic candidate40% success